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We present a single institution experience with 5-FU, mitomycin-C based chemoradiation for the primary treatment of elderly
patients with oesophageal cancer. Twenty-five patients with a median age of 77 years (range 66–88) with a diagnosis of stage II–III
squamous cell or adenocarcinoma of the oesophagus were treated at Memorial Sloan Kettering from 1996 to 2001 with two cycles
of concurrent 5-FU, mitomycin-C and 50.4Gy. Owing to age and comorbidity, these patients were not considered surgical
candidates. The Charlson comorbidity score was used to evaluate patient comorbidity. Nine patients (36%) experienced grade 3–4
haematologic toxicity. Of the 23 patients evaluable for response, 17 patients (68%) had a negative post-treatment endoscopy and CT
scan without evidence of progressive disease. Eleven patients (44%) are alive and 10 (40%) remain without evidence of recurrent or
progressive oesophageal cancer at a median follow-up of 35 months. The median overall survival was 35 months and 2-year survival
64%. There was no significant difference in overall survival between Charlson score p2 and those with a score X2( P¼0.10). Similar
survival was observed for patients with adenocarcinoma or squamous carcinoma. Primary chemoradiation with two cycles of 5-FU,
mitomycin-C, and 50.4Gy in elderly patients is an active regimen with moderate toxicity, despite the advanced age and heavy
comorbidity burden of this cohort. Patients with local/regional oesophageal cancer with adequate functional status should not be
excluded from potentially curative treatment based on age alone.
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The incidence of oesophageal adenocarcinoma has had the most
rapid rise of any solid tumour malignancy in the United States
(Devesa et al, 1998). Over 14550 Americans were diagnosed with
this malignancy in 2006 (Jemal et al, 2006). Most patients have
stage III or IV disease at presentation. Unfortunately, there has
been little change in 5-year survival, which remains less than 10%
(Enzinger and Mayer, 2003).
Elderly patients with early stage oesophageal cancer treated with
surgery alone appear to achieve similar survival benefit compared
to younger patients without increased mortality (Alexiou et al,
1998). However, most series indicate that a significantly smaller
proportion of elderly patients diagnosed with oesophageal cancer
is actually referred for oesophagectomy compared to younger
patients (Sabel et al, 2002; Bonavina et al, 2003), indicating
significant patient selection. Few series report patients’ coexisting
medical conditions (Poon et al, 1998, Ma et al, 2006). Most series
indicate comparable to higher rates of post-operative morbidity,
and comparable rates of post-operative mortality in patients over
the age of 70 referred for oesophagectomy (Jougon et al, 1997;
Kinugasa et al, 2001). Adenocarcinoma is the dominant histology
in Western surgical series in these patients. Several investigations
of elderly patients treated with radiation alone indicate no
difference in response or survival when compared to younger
patients (Hishikawa et al, 1991; Yamakawa et al, 1994).
The Radiation Therapy Oncology Group (RTOG) trial 85-01
established the superiority of chemotherapy with cisplatin, 5-FU
and concurrent radiation over radiation alone (Herskovic et al,
1992). Patients randomised to chemoradiation demonstrated
improved overall survival (26 vs 0% at 3 years) and median
survival (12.5 vs 9 months) compared to the radiation-alone arm.
This regimen has been considered the standard of care for
treatment of patients with locally advanced oesophageal cancer
treated without surgery. Unfortunately, given the substantial acute
toxicity of this regimen it has commonly been reserved for
treatment of younger patients with good performance status.
Toxicity on the RTOG trial was substantial. Sixty-four percent of
patients treated with chemoradiation experienced severe or life-
threatening side effects compared to 28% of patients treated with
radiation alone. Only 23% of patients enrolled were over age 70.
Little has been reported about the use of primary chemo-
radiotherapy without surgery in elderly patients with locally
advanced oesophageal and squamous cancers. In addition, limited
data are available regarding the response or tolerance of combined
modality chemoradiation in elderly patients with oesophageal
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scancer. One recent series indicated comparable post-operative
mortality rates even in patients over the age of 70 receiving
preoperative combined chemoradiotherapy followed by surgery
(Rice et al, 2005) compared to elderly patients undergoing surgery
alone.
Although the majority of cancers in the United States occur in
the elderly, older American are under-represented in clinical trials
(Hutchins et al, 1999). A study of the Southwest Oncology Group
(SWOG) compared the enrollment of older Americans onto SWOG
trials from 1993 to 1996 to the actual proportion of older persons
with cancer. Although patients over the age of 65 accounted for
63% of cancers in the United States, only 25% of patients enrolled
on SWOG trials were over 65 years. A European analysis
corroborates the under-representation of elderly patients entered
on clinical trials (Monfardini et al, 1995). Reasons for the under-
representation of elderly patients on clinical trials in oesophageal
cancer are unclear. Physician concern regarding comorbidities, the
possibility of increased toxicity, and lack of data supporting the
efficacy of treatment may be contributing factors.
To determine the tolerability and efficacy of chemoradiation in
this population, we reviewed our institutional experience over a
5-year period in persons over 65 years with locally advanced
oesophageal cancer treated with 5-FU, mitomycin, and concurrent
radiotherapy as primary treatment of oesophageal cancer. We
opted to employ the combination of 5-FU and mitomycin with
radiation, as small patient series with oesophageal cancer treated
with this regimen suggest a more favourable toxicity profile in
comparison to conventional 5-FU and cisplatin (Coia et al,
1991a,b). We defined an elderly population according to Social
Security and Medicare regulations as persons aged 65 years or
older.
MATERIALS AND METHODS
Given the age and comorbidity of this older patient population,
definitive chemotherapy and radiation was planned as primary
therapy without surgery. Patients 65 years and older diagnosed
with locally advanced oesophageal cancer at Memorial Sloan-
Kettering Cancer Center between January 1996 and April 2001,
who were selected to receive chemoradiation with two cycles of
5-FU and mitomycin as first-line treatment were included in this
analysis. Patients were treated in hospital for close monitoring
during the two cycles of chemotherapy, as many patients had
multiple comorbid conditions. Specifically 7 patients had a history
of arrhythmia, 13 had hypertension, 8 patients had documented
peripheral vascular and/or coronary artery disease, and 3 patients
had a history of heart failure.
Treatment regimen
Therapy consisted of 5-FU at a dose of 750–1000mgm
 2 per day
for 4 days given by continuous infusion weeks 1 and 5. Mitomycin
was given at a dose of 7–10mgm
 2 on days 1 and 29 of
chemoradiation.
Radiation therapy
Radiation therapy was delivered with megavoltage equipment
(15MV) using a multiple field technique. Patients were treated 5
days per week at 1.8Gy per day. All fields were treated each day,
and portal films were obtained of at least two fields per week, or
more often if needed. Treatment was delivered with four fields
(AP/PA and opposed laterals) such that the dose did not vary by
45% over the entire target volume. The dose was prescribed to the
isodose line that covered the volume at risk. Lung inhomogeneity
corrections were used.
The superior and inferior borders of the radiation field were
5cm beyond the primary tumour. The lateral, anterior, and
posterior borders of the field were X2cm beyond the borders of
the primary tumour. The tumour size was defined by endoscopic
ultrasound (EUS), barium swallow, or CT scan (whichever was
larger). The primary and the regional lymph nodes were included.
Pretreatment evaluation
All patients had an upper endoscopy. Ten patients also had EUS
performed at the discretion of their referring gastroenterologists.
All patients had CT scans of the chest and abdomen before
treatment and 11 patients had PET scans as part of their
pretreatment evaluation. Patients without EUS were clinically
staged as N1 on the basis of visible lymphadenopathy on CT scan,
and T3 on the basis of visible oesophageal mass on CT scan. Post-
treatment response was evaluated via endoscopy and CT scan.
Post-treatment evaluations were conducted 8–16 weeks after
completion of all treatment.
To give a descriptive analysis of this cohort’s comorbidity
burden, we used the Charlson comorbidity index (Charlson score;
Charlson et al, 1987). The Charlson score is a widely used
comorbidity scale validated to correlate with 1-year mortality risk
in cancer patients (Newschaffer et al, 1997; Reid et al, 2001).
Nineteen medical conditions generating a relative increased risk
of death are weighted, and calculated as four ordinal categories: 0,
1–2, 3–4, and 5þ.
Statistical analysis
To test if a Charlson score X2 was related to increased toxicity or
increased death, the Fisher’s exact test was used. Overall survival
was based on the Kaplan–Meier method. The log-rank test was
used to compare differences in length of survival between groups.
The t-test was performed to assess if increased age was related to
toxicity. All statistical analysis was performed using SAS Software
(SAS Institute, Cary, NC, USA).
Evaluation of response
Achievement of a complete response required a negative endo-
scopy and biopsy and CT scan without evidence of disease
progression or recurrence. Patients were seen in clinic every 3–6
months with follow-up endoscopies and CT scans. Surgery was not
planned in this elderly patient population with comorbidities.
RESULTS
Patients
Twenty-five patients over age 65 with locally advanced oesopha-
geal cancer were treated during this period. Patient age ranged
from 66 to 88 years (median 77 years). Twenty-three patients
(92%) were 70 years or older. There were 14 women and 11 men.
All patients had a minimum Karnofsky performance status of 70%.
Twelve patients had adenocarcinoma and 13 had squamous cell
cancer. Twenty-one patients (84%) had clinically staged T3/T4 or
N1 disease by EUS or CT scan. Baseline characteristics are listed in
Table 1.
The prevalence of comorbidity, defined as a Charlson score X1,
was 84%. The mean Charlson score was 2. Seventy-two percent of
patients had a Charlson score X2 and 36% percent of patients had
a Charlson score X3. Five patients (20%) were diabetic and 10
(40%) had chronic obstructive pulmonary disease. Twelve patients
(36%) had a prior or concurrent malignancy. Nine patients (36%)
had peripheral vascular or cerebrovascular disease. One patient
had a prior myocardial infarction and three patients (12%) had a
history of heart failure.
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sFifteen (60%) patients were active or former cigarette smokers
with a mean pack/year history of 18 years (range 10–100). Twenty-
one patients (84%) presented with dysphagia. Weight loss was
also notable in most patients with 15 (60%) experiencing a mean
10-pound decrease from baseline (range 5–30 pounds). Three
patients (15%) received feeding tubes for nutritional support
before initiation of treatment.
Treatment delivery
Twenty-two of 25 patients completed all planned treatment. For
cycle 1 of treatment patients received mitomycin 7–10mgm
 2 on
day 1 (3 patients 10mgm
 2, 19 patients 8mgm
 2, and 3 patients
7mgm
 2). A total of 750–1000mgm
 2 5-FU was given in days 1–4
(18 patients 750mgm
 2 and 7 patients 1000mgm
 2). Although
no planned dose selection was made in this retrospective series,
older patients were generally treated with lower chemotherapy
doses.
For cycle 2, three patients (15%) required dose attenuation. The
remainder of patients received the same dose as in cycle 1. One
patient had a 33% dose reduction of 5-FU from 750 to 500mgm
 2
due to excess gastrointestinal toxicity. Two patients required
omission of mitomycin from cycle 2 secondary to haematologic
and gastrointestinal toxicity, respectively.
Toxicity
All patients were evaluable for toxicity. Nine patients (36%)
required admission for toxicity management. Four patients
required admission after the first week of chemoradiation for
toxicity management (two neutropenic fever, one dehydration, one
heart failure management.) Five patients required admission for
toxicity management after the second course of chemoradiation
(two oesophagitis, one cellulitis, one radiation pneumonitis, one
neutropenic fever.) Nine patients (36%) required treatment delay.
All patients completed all planned radiotherapy. No patient
required a feeding tube during chemoradiation treatment.
Haematologic toxicity was moderate; mean haematologic nadirs
are provided in Table 2. Nine patients (36%) experienced grade 3
or 4 haematologic toxicity: neutropaenia 7 (six grade 4, one grade
3); thrombocytopaenia 2 (grade 4). No death related to treatment
toxicity was observed. Toxicity data are recorded in Table 2.
Treatment outcome and survival
Twenty-five patients completed chemoradiation and 23 patients
are evaluable for treatment response. Two patients were not
evaluable for response. One patient died 32 days after completion
of treatment secondary to heart failure related complications. A
second patient died 37 days after last treatment from complica-
tions related to ischemic heart disease. Although the post-
treatment CT scan was suspicious for disease progression, this
patient did not undergo post-treatment endoscopy.
Twenty-three patients had post-treatment CT scans and
endoscopies. Seventeen patients (68%) had no evidence of
persistent cancer on endoscopy and a CT scan without evidence
of disease progression. Three patients (15%) had evidence of a
major response at endoscopy, but had local persistence of their
tumours. Two of these patients underwent salvage therapy with
one patient achieving a complete response. The patient who
achieved a complete response to salvage treatment underwent two
applications of high-dose rate intraluminal brachytherapy to the
lower oesophagus for a total dose of 1000cGy. The other patient
who underwent salvage received two treatments of photodynamic
therapy. Unfortunately, she experienced worsening symptoms of
dysphagia and ultimately died of metastatic disease shortly
thereafter. The third patient underwent surgical resection for
residual carcinoma in situ and died from post-operative complica-
tions. The remaining three patients’ (15%) post-treatment evalua-
tions revealed persistent or progressive disease either on CT or
endoscopy.
Eleven patients are alive (44%) and 10 (40%) remain without
evidence of disease with a median follow-up of 32 months (range
18–62). Median overall survival for the entire cohort is 35 months
(95% CI, 14–66). One- and 2-year overall survival is 80% (95% CI,
64–96%) and 64% (95% CI, 45–83%), respectively. Median follow-
up for the entire group is 35 months (range 3–66). Survival
outcome was similar for patients with adenocarcinoma and
squamous carcinoma: of 14 patients who survived and remained
free for at least 2 years out from treatment, 6 had adenocarcinoma
(50% of 12 patients initially treated) and 8 had squamous
carcinoma (62% of 13 patients initially treated). Of seven patients
80 years or older at the start of therapy, three patients (43%) were
alive and free of disease for at least 2 years out from treatment (two
patients with adenocarcinoma and one with squamous cell
carcinoma). There was no significant difference in overall survival
between patients with a Charlson score p2 (median 43 months,
95% CI, 23–66) compared to those with a score X2 (median 34
months, 95% CI, 10 not reached), P¼0.10. There was a correlation
between Charlson score X2 and grade 3 or 4 toxicity (P¼0.03).
However, there was no correlation between Charlson score X2 and
hospital admission (P¼0.14). In addition, increased age did not
correlate to an increased risk of death (P¼0.46). Survival curves
are shown in Figures 1 and 2.
DISCUSSION
The National Cancer Database of the American College of
Surgeons, reveals that the mean age of patients with oesophageal
cancer is 67.3 years (Daly et al, 2000). Most patients present with
stage III or IV disease. Chemoradiation is the standard non-
surgical treatment for patients with locally advanced oesophageal
cancer (Coia et al, 2000). Almost 50% of patients treated with
standard therapy with continuous infusion 5-FU, cisplatin, and
Table 2 Haematologic toxicity (N¼25)
Mean Grade 3 Grade 4
Leukopaenia (kml
 1) 2.5 3 (12%) 4 (16%)
Granulocytopaenia (kml
 1) 1.4 6 (24%) 1 (4%)
Anemia (gdl
 1) 10.6 0 1 (4%)
Thrombocytopaenia (kml
 1) 110.0 0 2 (8%)
Table 1 Patient demographics
Median age (range) 77 (66–88)
Median Karnofsky performance status: 80 (70–90)
Adenocarcinoma:squamous 12:13
Stage
T4N1 2 (8%)
T3NX 5 (20%)
T3N1 10 (40%)
T3N0 4 (16%)
T2N0 4 (16%)
Comorbidities
Diabetes 5 (20%)
Pulmonary disease 6 (24%)
Coronary artery or peripheral vascular 9 (36%)
Disease
Median Charlson score 2
Charlson score 2 or more 18 (72%)
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threatening haematologic toxicity raising the question regarding
tolerance of therapy in an elderly population with oesophageal
cancer.
Our retrospective data suggest that chemoradiation with 5-FU
and mitomycin in geriatric oesophageal cancer patients is both
tolerable and efficacious. Although patient selection is clearly
an issue in a retrospectively treated series of patients, nonetheless
our patients had a median age of 77 years and 84% presented
with at least one comorbid condition. The majority of patients
were not surgical candidates due to advanced age and medical
comorbidities despite locally advanced disease. Treatment was
tolerable with moderate toxicity observed. Grade 4 toxicity
was observed in only four patients (16%) and there were no
treatment-related deaths. All 25 patients completed treatment
and only 3 patients (12%) required dose adjustment. With a
1-year overall survival rate of 80%, 2-year overall survival of
64%, 40% of patients remain alive without evidence of disease.
Of note, of the 15 patients treated with 7 or 8mgm
 2 mitomycin
and 750mgm
 2 per day 5-FU, there was no grade 4 toxicity
observed and only two patients (8%) required admission for
toxicity management. Two-year survivorship was comparable for
adenocarcinoma and squamous cell carcinoma, and patients 80
years and older also achieved a similar 2-year survival. Survival
results in this series meet or exceed the survival reported in the
original RTOG 85–01 trial, again likely a function of patient
selection and also of potentially superior staging of patients in this
series, using EUS, more modern CT scan imaging, and PET scan
staging.
There are few data regarding the tolerability of 5-FU and
mitomycin chemoradiation in this elderly patient population.
Published studies in other malignancies suggest benefit for
treatment of elderly patients. A retrospective analysis of elderly
colon cancer Medicare patients revealed only a modest increase in
toxicity for those undergoing adjuvant chemotherapy (Schrag et al,
2001). Two European rectal cancer trials observed a benefit for
elderly persons treated with 1 cycle of 5-FU and mitomycin with
radiation (Valentini et al, 1997; Allal et al, 1999). All patients were
over the age of 75. Neither trial reported grade 4 toxicity or any
treatment-related death. Results observed were consistent with that
reported for younger patients (Coia et al, 1991a,b; Smith et al,
1998).
This regimen may be an appropriate alternative for oesophageal
cancer patients who cannot tolerate standard therapy with
cisplatin and 5-FU chemoradiation, and for older patients who
have a heavy comorbidity burden and are deemed non-surgical
candidates. In addition, two cycles of brief in-patient treatment
weeks 1 and 5 allows for close patient monitoring. Recent studies
have from our institution have also indicated that using non-5-FU
containing chemotherapy regimens with concurrent radiotherapy
may also have a potential to lower toxicity of combined
chemoradiotherapy. In two phase I trials combining either weekly
paclitaxel (Brenner et al, 2004) or weekly irinotecan (Ilson et al,
2003) with a weekly schedule of relative low-dose cisplatin and
concurrent radiotherapy, gastrointestinal, and haematologic toxi-
cities were relatively mild. These regimens also offer promise as an
alternative to conventional 5-FU and cisplatin. Recent data also
continue to support the use of 5-FU and mitomycin as a
radiosensitising regimen in gastrointestinal cancers. A recent US
Intergroup trial in anal cancer compared conventional 5-FU,
mitomycin, and radiation to the use of induction chemotherapy
with 5-FU and cisplatin, followed by combined 5-FU, cisplatin and
radiation (Ajani et al, 2006). The 5-FU and cisplatin arm had an
inferior outcome compared to conventional 5-FU and mitomycin,
and the results underscore the use of this regimen as a treatment
standard in anal cancer.
Older cancer patients may not be offered or may defer treatment
secondary to the perception of increased toxicity. Our responses to
treatment appear comparable to published chemoradiation studies
observed in younger patients. Our investigation does not reveal
increased haematologic toxicity from chemoradiation in this
elderly cohort. Because of the retrospective nature of this analysis,
non-haematologic toxicity data may be under-reported, as patients
were not treated in the context of a prospective clinical trial.
However, there was no need for placement of feeding tubes during
chemoradiation treatment, although three patients required
feeding tubes before initiation of therapy secondary to dysphagia
for nutrition support.
Limitations regarding the generalisability of our results include
the small cohort size, and the retrospective nature of this analysis
resulting in significant patient selection for therapy tolerance.
However, the majority of patients were over 70 years (92%), with
locally advanced disease (84%) and more than 1 comorbid
condition (84%). The median overall survival of 35 months
observed in this elderly cohort suggest similar results to that
observed in more toxic chemoradiation regimens in much younger
oesophageal cancer patients. There is a need for clinical
investigations evaluating the role of chemoradiation in elderly
oesophageal cancer patients.
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